文献速递认知障碍与谵妄多重用药

澳大利亚养老院全国改革期间精神药物使用趋势(2018-2022):428家机构分析

National Aged Care Reforms and Trends in Psychotropic Medication Use in 428 Residential Age Care Facilities, 2018-2022.
PubMed 文献 · J Am Med Dir Assoc · 2025-09-12

该回顾性队列研究利用2018年1月至2022年12月澳大利亚7个州/领地428家住宿养老机构52,201名居民的每日给药数据,评估全国改革(含抗精神病药强制报告)期间四类精神药物月度给药率变化。结果显示,伴与不伴痴呆居民的 antipsychotics(抗精神病药)、sedatives and anxiolytics(镇静催眠药与抗焦虑药)及 antiseizure medication(抗癫痫药)给药均显著下降,但痴呆患者抗抑郁药使用上升,提示可能存在药物类别转换。

要点

  • 2018-2022年澳大利亚养老院抗精神病药、镇静抗焦虑药及抗癫痫药给药率显著下降。
  • 痴呆患者抗抑郁药使用上升(RAPC 11.9%),非痴呆者无变化。
  • 需监测是否出现精神药物类别间转换等非预期后果。

核心结论

  • 2018至2022年间,澳大利亚住宿养老机构中三类精神药物使用下降,但痴呆患者抗抑郁药使用增加,可能作为化学约束的一种形式。

研究设计与样本

  • 回顾性队列研究,使用2018年1月至2022年12月澳大利亚7个州/领地428家住宿养老机构52,201名居民的常规电子给药数据。

主要发现

  • 痴呆患者抗精神病药相对月均百分比变化(RAPC)为-34.6%(95%CI:-41.1,-28.2;P<.001)。
  • 痴呆患者镇静抗焦虑药RAPC为-38.5%(95%CI:-48.3,-28.7;P<.001)。
  • 痴呆患者抗癫痫药RAPC为-28.6%(95%CI:-38.1,-19.1;P<.001),抗抑郁药RAPC为11.9%(95%CI:5.44,18.4;P<.001)。
  • 非痴呆患者抗精神病药RAPC为-31.7%(95%CI:-40.2,-23.1;P<.001),镇静抗焦虑药RAPC为-35.3%(95%CI:-42.8,-27.9;P<.001),抗癫痫药RAPC为-12.5%(95%CI:-20.2,-4.82;P<.001),抗抑郁药无变化。

临床怎么用

  • 在老年医学科评估痴呆患者精神行为症状时,应关注抗抑郁药是否被用作化学约束替代。
  • 结合全国质量指标项目持续监测精神药物类别转换,避免非预期后果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To assess changes in the prevalence of psychotropic medication administration in Australian residential aged care (RAC) during a period of national reforms, including the introduction of mandatory reporting of antipsychotic use. DESIGN: A retrospective cohort study using routinely collected electronic medication administration data. SETTING AND PARTICIPANTS: Daily medication administration data for 52,201 residents of 428 RAC facilities in 7 Australian states and territories between January 2018 and December 2022. METHODS: We estimated the percentage of residents administered psychotropic medications from 4 classes (antipsychotics, sedatives and anxiolytics, antiseizure medication, antidepressants) at least once in each calendar month. The relative monthly average percentage change (RAPC) in prevalence by dementia status was the primary outcome. RESULTS: Significant reductions occurred in the administration of antipsychotic, sedative and anxiolytic, and antiseizure medication to residents with and without dementia between 2018 and 2022. However, administration of antidepressants increased in residents with dementia over the same period. Residents with dementia experienced an RAPC of -34.6% (95% CI: -41.1, -28.2; P < .001) for antipsychotics, -38.5% (95% CI: -48.3, -28.7; P < .001) for sedatives and anxiolytics, -28.6% (95% CI: -38.1, -19.1; P < .001) for antiseizure medication, and 11.9% (95% CI: 5.44, 18.4; P < .001) for antidepressants. Residents without dementia experienced an RAPC of -31.7% (95% CI: -40.2, -23.1; P < .001) for antipsychotics, -35.3% (95% CI: -42.8, -27.9; P < .001) for sedatives and anxiolytics, -12.5% (95% CI: -20.2, -4.82; P < .001) for antiseizure medication, and no change for antidepressants. CONCLUSIONS AND IMPLICATIONS: Between 2018 and 2022, use of 3 psychotropic medication classes declined in Australian RAC. However, antidepressant use increased in people with dementia, potentially as a form of chemical restraint. Ongoing monitoring of the national Quality Indicator program and other initiatives is crucial to ensure there are no unintended consequences such as switching between psychotropic medication classes.

来源:J Am Med Dir Assoc,查看原文。版权归原作者所有。

引用

  1. Raban MZ, Rahman B, Wabe N, et al. National Aged Care Reforms and Trends in Psychotropic Medication Use in 428 Residential Age Care Facilities, 2018-2022. J Am Med Dir Assoc. 2025. PMID: 40882947. doi:10.1016/j.jamda.2025.105832

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。